Epynext therapeutics (2022)
Epynext Therapeutics：创新抗体疗法平台
法国生物技术公司Epynext Therapeutics（成立于2022年）开发了一套独特的抗病原体中和性治疗抗体生成平台。该平台的核心在于整合了三种关键技术方法：
1. 膜抗原选择：精准筛选病原体表面的关键膜抗原作为靶点。
2. 重组蛋白脂质体体外合成：通过体外技术合成包含目标抗原的重组蛋白脂质体，模拟病原体膜的自然结构。
3. “类人”中和抗体生产：基于上述制备的抗原，生成具有高度中和活性且特性接近人源抗体的治疗性抗体。
这一整合性平台旨在更高效、更具针对性地开发对抗病原体（如病毒）的新型抗体疗法。
Epynext Therapeutics (2022) – Company Digest
Epynext Therapeutics is developing a novel, integrated platform for generating neutralizing therapeutic antibodies against pathogens. The company’s approach uniquely combines three core methodologies:
1. Targeted Antigen Selection: The process begins with the strategic selection of specific membrane antigens from the target pathogen.
2. Recombinant Protein Synthesis: Following selection, the company employs *in vitro* synthesis to produce recombinant proteoliposomes. These artificial structures mimic the native viral or bacterial membrane, presenting the chosen antigen in a more natural, immunologically relevant conformation.
3. Antibody Generation: This platform is designed to yield neutralizing antibodies with "human-like" characteristics, which is a critical factor for improving therapeutic efficacy and reducing potential immunogenicity in patients.
This combined methodology aims to streamline and enhance the discovery of potent antibody candidates, positioning Epynext in the competitive field of infectious disease therapeutics.
Epynext propose une approche unique d’obtention d’anticorps thérapeutiques neutralisants anti-pathogènes combinant trois méthodes : choix de l’antigène membranaire, synthèse in vitro des protéoliposomes recombinants, production d’anticorps neutralisants «human-like».